Showing 2745 results
-
Ad hoc release /Ad hoc announcement pursuant to Art. 53 LR CANOPY-1 Phase III study did not meet its primary endpoints of overall survival (OS) and progression-free survival (PFS)…
-
Press release /
Novartis announces FDA and EMA filing acceptances of Beovu® for patients with diabetic macular edema
Regulatory decisions for Beovu (brolucizumab) in diabetic macular edema (DME) are expected in mid-2022 in the US and Europe DME is the leading cause of blindness in adults in developed… -
Press release /Novartis and Medicines for Malaria Venture (MMV) report positive Phase 2b study results for novel non-artemisinin combination to treat uncomplicated malariaIn the Phase 2b study conducted in children…
-
Press release /New findings show Cosentyx® (secukinumab) 300 mg single dose autoinjector (the UnoReady® pen) resulted in superior efficacy vs placebo1 Patient satisfaction with 300 mg autoinjector…
-
Press release /Data analysis shows that preventing the symptoms of CSU (achieving complete control) improves overall health-related quality of life (HRQoL); including sleep and work productivity, among other…
-
Press release /Acquisition underscores Novartis commitment to using optogenetics-based therapies to restore vision to patients with advanced blindness Novartis gains one pre-clinical optogenetic AAV gene therapy…
-
Press release /Cette acquisition souligne l’engagement de Novartis à utiliser des thérapies basées sur l’optogénétique pour redonner la vue aux patients atteints de cécité avancéeNovartis acquiert un programme…
-
Press release /Novartis will present 41 abstracts from a wide-ranging multiple sclerosis (MS) portfolio, including new data on Kesimpta® (ofatumumab) and Mayzent® (siponimod)Novartis will be commencing Phase III…
-
Press release /Company previously disclosed settlement agreement in principle and fully provisioned for this resolution Basel, October 1, 2021 – Sandoz Inc., the U.S. subsidiary of Sandoz,…
-
Press release /Results from a Phase IIb study show all remibrutinib doses provided significant improvements in UAS7 change from baseline at week 4 and week 12 compared to placebo, and a favorable safety profile…